8-K
Entry into a Material Definitive Agreement
Show detailsHide details
1.01 Entry into a Material Definitive Agreement · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits
09061GAH4
Biomarin Pharmaceutical Inc
Could not find a ticker for this position, may be a filing error
A biotechnology company focused on rare genetic diseases, BioMarin makes enzyme-replacement and gene therapies—including VOXZOGO, the first drug approved to treat achondroplasia (dwarfism) in children—alongside treatments like VIMIZIM and NAGLAZYME used by patients with rare metabolic disorders. Founded in 1997 in Marin County, California, the company's name blends "bio" for biotechnology with "Marin," the county where it got its start. Its early founders deliberately took on rare diseases that bigger drugmakers ignored, and the company has since grown into one of the world's largest rare-disease biotechs.
CONVERTIBLEUnderlying: BMRNCUSIP: 09061GAH4HealthcareUS1 derivative reporter
0.599% Senior Subordinated Convertible Notes Due 2024